Cart
sales@molnova.com
Pamrevlumab
CAS No. 946415-13-0
Pamrevlumab( —— )
Catalog No. M36727 CAS No. 946415-13-0
Pamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 211 | Get Quote |
|
| 5MG | 392 | Get Quote |
|
| 10MG | 629 | Get Quote |
|
| 25MG | 908 | Get Quote |
|
| 50MG | 1260 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePamrevlumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionPamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
-
DescriptionFG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number946415-13-0
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sgalla G, et, al. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2020 Aug;29(8):771-777.?
molnova catalog
related products
-
Phenoxodiol
Phenoxodiol activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis(XIAP), disrupts FLICE inhibitory protein(FLIP) expression, and sensitizes the cancer cells to Fas-mediated apoptosis.
-
3-?O-?Acetyloleanoli...
3-O-acetyloleanolic acid dose-dependently inhibited the viability of HCT-116 cells. Apoptosis was characterized by detection of cell surface annexin V and sub-G1 apoptotic cell populations.
-
ZDLD20
ZDLD20 is an orally active and selective CDK4 inhibitor, a β-carboline analog with anti-HCT116 and anticancer activity that inhibits colony formation, inhibits invasion and migration, induces apoptosis, and prevents the G1 phase of the cell cycle.
